This study has several treatment arms and each treatment arm has 2 stages. During Stage 1 - AB928 plus zimberelimab alone, AB928 plus zimberelimab with or without a standard of care treatment (enzalutamide or docetaxel), or AB928 plus AB680 with or without zimberelimab will be administered to participants with mCRPC.
During Stage 2 - Additional participants with mCRPC may receive an AB928-based combination therapy evaluated in Stage 1 or, a standard of care treatment.
A pharmacokinetic (PK) Sub-Study (AB928 plus zimberelimab) will be conducted separately.
Treatment may continue until unacceptable toxicity or progressive disease, or other reasons specified in the protocol.
How understandable was the trial content above?
Hard to understand
Easy to understand